IL13 and asthma: Dupilumab, blocking IL-4 and Il-13 from binding to its receptors, was the first biologic approved for moderate to severe AD, and Omalizumb, anti- IgE monoclonal antibody, was the first biologic approved for the treatment of asthma in the Unated States and the European Union [81].